18th Feb，2020– Can-Fite BioPharma Ltd. issued an announcement, which is summarized as follows:
Chong Kun Dang Pharmaceuticals (CKD) (Korean Stock Exchange: 185750.KS) of South Korea, has licensed the distribution rights to Namodenoson in South Korea for the treatment of liver cancer and NASH in a deal totaling $6 million in upfront and milestone payments, plus a transfer price for delivering finished products to CKD. The Company has received $2 million from CKD to date for Namodenoson in the treatment of liver cancer and NASH.
Can Fite plans to release data from its Phase II study of Namodenoson in NASH patients during this quarter. The multicenter, randomized, double-blinded, placebo-controlled, dose-finding efficacy and safety study has enrolled 60 patients with NAFLD (non-alcoholic fatty liver disease) with or without NASH. Patients who suffer from NAFLD/NASH with evidence of active inflammation are treated twice daily with 12.5 mg or 25 mg of oral Namodenoson, or placebo for 12 weeks. The primary endpoint of the Phase II study is the anti-inflammatory effect of the drug, as determined by mean percent change from baseline in ALT blood levels and safety. Secondary endpoints include percentage change from baseline of liver fat, as measured by MRI-PDFF (proton density fat fraction).
The original website link:
https://ir.canfite.com/press-releases/detail/888/can-fite-granted-patent-allowance-for-its-nash-drug-namodenoson-in-south-korea-results-of-its-nash-phase-ii-study-are-expected-this-quarter